Spotlight
CRISPR-associated transposons, CASTs, are one of the more elegant tools molecular biology has borrowed from bacteria. A transposon is a piece of DNA that copies itself into a genome; bolt a CRISPR guide onto it, and you get a way to paste a chosen sequence into a chosen spot without the double-strand breaks that make conventional gene editing messy. One type-I-F system, PseCAST, works unusually well in human cells, which makes it a promising insertion tool. Yet nobody quite knew how the machine at its heart, the transposase, actually does its job.
A study in Nature Communications from Irma Querques 's group at the Max Perutz Labs Vienna and University of Vienna, with collaborators in Zurich and at Columbia University, works out that mechanism in detail. Using cryo-electron microscopy and biochemical reconstitution, the team, led by Mateusz Walter with Giada Finocchio and Seraina Oberli, watched the transposase, the enzyme that does the moving, latch onto both ends of the transposon and cut it free of the surrounding DNA, the first step in relocating it.
What they found reframes what the tool is. The transposase does not sit passively waiting for instructions. The transposon's own DNA ends drive the assembly of the machine that will move them, a sequence of molecular checkpoints that gate the cutting until everything is correctly in place. The element, in effect, regulates its own leap. To describe that doubling of roles, Querques reaches for Schrödinger, who in 1944 saw the same fusion in the genetic code itself: "law-code and executive power" or, in his other image, "architect's plan and builder's craft," in one.
For anyone hoping to engineer CASTs into precise insertion tools, this self-regulation is the point. The efficiency that makes PseCAST attractive is not a property the designer imposes from outside; it is built into how the transposon controls itself, and the checkpoints the team identified are exactly the handles a future engineer would turn. The same structural detail explains why a lab-evolved variant of the transposase works better than the natural one. A tool worth using, it turns out, is one that was already doing half the work on its own.
→ Walter, Finocchio, Oberli et al., Nature Communications, 2026
Radar Scans
WWTF Insight
This fortnight's Crossref data brought forward a paper by the Social, Cognitive and Affective Neuroscience Unit (SCAN-Unit), funded in part through a WWTF Vienna Research Group (VRG13-007) established by the late Christoph Eisenegger. The grant was discontinued after his death, but Claus Lamm 's unit has carried the work forward ever since and in his honour. The group has spent years mapping what placebo analgesia does and, just as tellingly, what it does not. Their latest, led by Helena Hartmann, PhD with Alessio Proposito and Federica Riva, asks whether a placebo that dampens pain also changes how accurately people read an inner bodily signal, the heartbeat. It does not. Trained on pain, the placebo effect stays with pain; it does not spill over into interoception more broadly. That is a useful negative result: it marks a boundary on how far a placebo reaches, rather than letting the effect stand as a vague, all-purpose modulator.
Stray Signal
Evolutionary highways, and the keys to the car
A team of scientists at the Department of Neuroscience and Developmental Biology University of Vienna compared 5,821 animal genomes and found that genomes evolve along a few irreversible routes: chromosomes fuse and mix, and can never quite return to where they began. Darrin T. Schultz and Oleg Simakov lay this out in Science Advances as a map, each animal a point placed by the shape of its chromosomes. What is easy to miss is the second gift underneath the first. What draws the map, the software, the genome database, the interactive version itself, is all released openly, down to the code that turns raw genomes into coordinates. Most papers ask you to trust the figure. This one hands over the instrument that made it, and invites you to check.
→ Schultz, Blümel, Destanović et al., Science Advances, 2026